Mdr-2 Inhibitors

Common Mdr-2 Inhibitors include, but are not limited to Troglitazone CAS 97322-87-7, Glyburide (Glibenclamide) CAS 10238-21-8, Losartan CAS 114798-26-4, Rifampicin CAS 13292-46-1 and Lovastatin CAS 75330-75-5.

Mdr-2, commonly known as Multidrug Resistance Protein 2 (MDR2) or ABCB4, is a protein that belongs to the ATP-binding cassette (ABC) transporter family. These transporters are membrane-bound proteins responsible for the active transport of various substrates across the cellular membranes, utilizing the energy from ATP hydrolysis. Mdr-2 specifically is an essential phospholipid flippase that translocates phosphatidylcholine from the inner to the outer leaflet of the bile canaliculus membrane in hepatocytes. This process plays a critical role in the secretion of phospholipids into bile, which is essential for the solubilization and secretion of cholesterol and the prevention of bile salt-induced membrane damage.

Mdr-2 inhibitors are molecules designed to target and suppress the functionality of the Mdr-2 protein. By inhibiting the action of Mdr-2, these compounds can impact the transport and secretion of phospholipids into the bile, which may affect bile composition and properties. Inhibition of Mdr-2 can lead to altered bile fluidity, causing imbalances in the bile composition, which might result in various cellular and metabolic responses. The action of Mdr-2 inhibitors could provide insights into the exact mechanisms and significance of phospholipid translocation in bile formation and its broader implications in liver physiology. Researching Mdr-2 inhibitors can also help in understanding the broader role of ABC transporters in cellular processes, given the importance of these transporters in a variety of physiological functions and their involvement in several cellular pathways.